NCT01045018View on ClinicalTrials.gov

A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

August 31, 2009

Conditions
Mild to Moderate Ulcerative Colitis
Interventions
DRUG

Placebo

placebo 400 mg

DRUG

Mesalamine

DRUG

Mesalamine

Sponsors
All Listed Sponsors
collaborator

Eagle Pharmaceuticals, Inc.

INDUSTRY

lead

EMET Pharmaceuticals, LLC

INDUSTRY

NCT01045018 - A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter